Jennifer L. Sherr, MD, PhD, and other investigators shared the latest data from the first randomized controlled trial of a sodium-glucose cotransporter protein-2 (SGLT2) inhibitor in adolescents with type 1 diabetes at the 84th Scientific Sessions.

Despite a lack of improvement in glycemic management in TIGHT, Guillermo Umpierrez, MD, CDCES, MACP, FACE, said he was optimistic about the future of determining hypoglycemia and hyperglycemia for hospitalized patients with diabetes.

Investigators presented findings from the first-ever dedicated kidney outcomes trial with a glucagon-like peptide-1 (GLP-1) receptor agonist. The trial was stopped early for clear positive efficacy, including slowed progression of kidney disease.

Multiple cardiovascular trials suggested the potential of fenofibrate in treating diabetic retinopathy and informed the hypothesis for LENS, explained Principal Investigator David Preiss, MBChB, MRCP, FRCPath, PhD.

Two trials of semaglutide show similar improvement in heart failure symptoms and weight loss in patients with BMI >30 who have heart failure with preserved ejection fraction with or without diabetes, reported Mikhail N. Kosiborod, MD, and other investigators.

Semaglutide is best known as a weight loss drug, yet SELECT was not a weight loss study. It was a secondary cardioprevention trial, explained Donna H. Ryan, MD, one of the experts presenting results from SELECT.

The drug has been shown to improve sleep apnea severity and related cardiometabolic issues in people with moderate-to-severe obstructive sleep apnea, reported investigators including Atul Malhotra, MD, and Louis J. Aronne, MD, FACP, DABOM.

Study Chair Irl B. Hirsch, MD, reported that inhaled insulin may be good for patients who are engaged in their diabetes self-management and want to reduce hyperglycemia even further, and for patients who want an alternative to a pump.

David Preiss, MBChB, MRCP, FRCPath, PhD, will highlight results from the LENS trial and the efficacy of fenofibrate in the treatment of diabetic retinopathy in a Friday, June 21, symposium.